Elcar (L-Carnitine)

Adult administration

1. Primary and secondary carnitine deficiency Myocardial metabolic disorder due to ischemic heart disease: angina, acute myocardial infarction Adults: Administer 2∼3 grams per day of L-carnitine in 2~3 divided doses by intramuscular or intravenous injection. Adjust the dose as appropriate according to age and symptoms. 2. Treatment of carnitine deficiency in patients with end-stage renal disease undergoing hemodialysis Initially, administer 10∼20 milligrams/kilogram intravenously over 2∼3 minutes at the end of each hemodialysis session. The dose may be adjusted according to the plasma L-carnitine level before hemodialysis.

When using this medication as an injection, care must be taken to avoid glass fragments mixing when cutting the glass container, so as not to allow glass pieces to enter the body. Extra caution is required, especially for children or the elderly. This medication should not be used in patients who have allergic reactions or hypersensitivity to it. Some patients may experience temporary nausea or vomiting, and, rarely, changes in body odor or symptoms of gastritis have been reported. Patients with a history of seizures should be cautious as using this medication may increase the frequency or severity of seizures. Various side effects can occur in chronic hemodialysis patients, which include abdominal pain, allergic reactions, headaches, infections, and injection site pain. Cardiac-related issues may include arrhythmias, palpitations, hypertension, or hypotension. Gastrointestinal symptoms such as loss of appetite, constipation, diarrhea, indigestion, nausea, and vomiting may occur, and blood in stool or gastrointestinal lethargy can happen rarely. Musculoskeletal symptoms such as myalgia or leg cramps, along with neurological symptoms like anxiety, dizziness, and insomnia, have also been reported. Respiratory symptoms may include increased coughing, shortness of breath, bronchitis, and rhinitis, while skin reactions may manifest as rashes or itching. The safety of this drug during pregnancy has not been sufficiently established, therefore it should only be used in pregnant or potentially pregnant women when the therapeutic benefit outweighs the risks. In addition, breastfeeding women should use this medication carefully as it may pass into breast milk.

• Temporary areas
• vomiting
• body odor
• gastritis
• seizures
• abdominal pain
• accidental injuries
• allergic reactions
• asthma
• back pain

This medication is sensitive to light, so it should be stored in a sealed container that blocks light. Additionally, it is important to maintain a temperature of 1 to 30 degrees Celsius during storage.

Appearance

A colorless to pale yellow clear liquid in a transparent brown glass ampoule injection

Package unit

Domestic - 5 milliliters/ampoule [5 mL X 10 ampoules], Export - 5 milliliters/ampoule [5 mL X 10 ampoules], Export - 5 milliliters/ampoule [5 mL X 25 ampoules]